Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

Abstract Background Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). P...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon, François-Clément Bidard
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2021-03-01
Serie:	Breast Cancer Research
Soggetti:	Circulating tumor DNA Breast cancer Palbociclib-fulvestrant Treatment follow-up Precision medicine
Accesso online:	https://doi.org/10.1186/s13058-021-01411-0
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!